Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Erratum for Mor et al., "Identification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids".

Mor V, Rella A, Farnoud AM, Singh A, Munshi M, Bryan A, Naseem S, Konopka JB, Ojima I, Bullesbach E, Ashbaugh A, Linke MJ, Cushion M, Collins M, Ananthula HK, Sallans L, Desai PB, Wiederhold NP, Fothergill AW, Kirkpatrick WR, Patterson T, Wong LH, Sinha S, Giaever G, Nislow C, Flaherty P, Pan X, Cesar GV, de Melo Tavares P, Frases S, Miranda K, Rodrigues ML, Luberto C, Nimrichter L, Del Poeta M.

MBio. 2018 Mar 13;9(2). pii: e00188-18. doi: 10.1128/mBio.00188-18. No abstract available.

2.

The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis.

Koselny K, Green J, DiDone L, Halterman JP, Fothergill AW, Wiederhold NP, Patterson TF, Cushion MT, Rappelye C, Wellington M, Krysan DJ.

Antimicrob Agents Chemother. 2016 Nov 21;60(12):7115-7127. Print 2016 Dec.

3.

Repurposing auranofin as an antifungal: In vitro activity against a variety of medically important fungi.

Wiederhold NP, Patterson TF, Srinivasan A, Chaturvedi AK, Fothergill AW, Wormley FL, Ramasubramanian AK, Lopez-Ribot JL.

Virulence. 2017 Feb 17;8(2):138-142. doi: 10.1080/21505594.2016.1196301. Epub 2016 Jun 7.

4.

Voriconazole minimum inhibitory concentrations are predictive of treatment outcome in experimental murine infections by Candida glabrata.

Sanchis M, Capilla J, Castanheira M, Martin-Vicente A, Sutton DA, Fothergill AW, Wiederhold NP, Guarro J.

Int J Antimicrob Agents. 2016 Apr;47(4):286-8. doi: 10.1016/j.ijantimicag.2015.12.020. Epub 2016 Feb 21.

PMID:
26976780
5.

The Investigational Fungal Cyp51 Inhibitor VT-1129 Demonstrates Potent In Vitro Activity against Cryptococcus neoformans and Cryptococcus gattii.

Lockhart SR, Fothergill AW, Iqbal N, Bolden CB, Grossman NT, Garvey EP, Brand SR, Hoekstra WJ, Schotzinger RJ, Ottinger E, Patterson TF, Wiederhold NP.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2528-31. doi: 10.1128/AAC.02770-15. Print 2016 Apr.

6.

Effects of Treated versus Untreated Polystyrene on Caspofungin In Vitro Activity against Candida Species.

Fothergill AW, McCarthy DI, Albataineh MT, Sanders C, McElmeel M, Wiederhold NP.

J Clin Microbiol. 2016 Mar;54(3):734-8. doi: 10.1128/JCM.02659-15. Epub 2016 Jan 13.

7.

Update from the Laboratory: Clinical Identification and Susceptibility Testing of Fungi and Trends in Antifungal Resistance.

Albataineh MT, Sutton DA, Fothergill AW, Wiederhold NP.

Infect Dis Clin North Am. 2016 Mar;30(1):13-35. doi: 10.1016/j.idc.2015.10.014. Epub 2015 Dec 29. Review.

PMID:
26739605
8.

The novel arylamidine T-2307 demonstrates in vitro and in vivo activity against echinocandin-resistant Candida glabrata.

Wiederhold NP, Najvar LK, Fothergill AW, Bocanegra R, Olivo M, McCarthy DI, Fukuda Y, Mitsuyama J, Patterson TF.

J Antimicrob Chemother. 2016 Mar;71(3):692-5. doi: 10.1093/jac/dkv398. Epub 2015 Nov 29.

9.

First Detection of TR34 L98H and TR46 Y121F T289A Cyp51 Mutations in Aspergillus fumigatus Isolates in the United States.

Wiederhold NP, Gil VG, Gutierrez F, Lindner JR, Albataineh MT, McCarthy DI, Sanders C, Fan H, Fothergill AW, Sutton DA.

J Clin Microbiol. 2016 Jan;54(1):168-71. doi: 10.1128/JCM.02478-15. Epub 2015 Oct 21.

10.

Voriconazole and posaconazole therapy for experimental Candida lusitaniae infection.

Sanchis M, Guarro J, Sutton DA, Fothergill AW, Wiederhold N, Capilla J.

Diagn Microbiol Infect Dis. 2016 Jan;84(1):48-51. doi: 10.1016/j.diagmicrobio.2015.09.010. Epub 2015 Sep 18.

PMID:
26456387
11.

VT-1161 Protects Immunosuppressed Mice from Rhizopus arrhizus var. arrhizus Infection.

Gebremariam T, Wiederhold NP, Fothergill AW, Garvey EP, Hoekstra WJ, Schotzinger RJ, Patterson TF, Filler SG, Ibrahim AS.

Antimicrob Agents Chemother. 2015 Dec;59(12):7815-7. doi: 10.1128/AAC.01437-15. Epub 2015 Sep 14.

12.

Evaluation of VT-1161 for Treatment of Coccidioidomycosis in Murine Infection Models.

Shubitz LF, Trinh HT, Galgiani JN, Lewis ML, Fothergill AW, Wiederhold NP, Barker BM, Lewis ER, Doyle AL, Hoekstra WJ, Schotzinger RJ, Garvey EP.

Antimicrob Agents Chemother. 2015 Dec;59(12):7249-54. doi: 10.1128/AAC.00593-15. Epub 2015 Sep 14.

13.

Detection of triazole resistance among Candida species by matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS).

Saracli MA, Fothergill AW, Sutton DA, Wiederhold NP.

Med Mycol. 2015 Sep;53(7):736-42. doi: 10.1093/mmy/myv046. Epub 2015 Jul 10.

PMID:
26162474
14.

Identification of a New Class of Antifungals Targeting the Synthesis of Fungal Sphingolipids.

Mor V, Rella A, Farnoud AM, Singh A, Munshi M, Bryan A, Naseem S, Konopka JB, Ojima I, Bullesbach E, Ashbaugh A, Linke MJ, Cushion M, Collins M, Ananthula HK, Sallans L, Desai PB, Wiederhold NP, Fothergill AW, Kirkpatrick WR, Patterson T, Wong LH, Sinha S, Giaever G, Nislow C, Flaherty P, Pan X, Cesar GV, de Melo Tavares P, Frases S, Miranda K, Rodrigues ML, Luberto C, Nimrichter L, Del Poeta M.

MBio. 2015 Jun 23;6(3):e00647. doi: 10.1128/mBio.00647-15. Erratum in: MBio. 2018 Mar 13;9(2):.

15.

The novel arylamidine T-2307 maintains in vitro and in vivo activity against echinocandin-resistant Candida albicans.

Wiederhold NP, Najvar LK, Fothergill AW, Bocanegra R, Olivo M, McCarthy DI, Kirkpatrick WR, Fukuda Y, Mitsuyama J, Patterson TF.

Antimicrob Agents Chemother. 2015 Feb;59(2):1341-3. doi: 10.1128/AAC.04228-14. Epub 2014 Dec 1.

16.

The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant Candida albicans.

Wiederhold NP, Najvar LK, Fothergill AW, McCarthy DI, Bocanegra R, Olivo M, Kirkpatrick WR, Everson MP, Duncanson FP, Patterson TF.

Antimicrob Agents Chemother. 2015 Jan;59(1):690-2. doi: 10.1128/AAC.03944-14. Epub 2014 Oct 20.

17.

Epidemiology and outcome of systemic infections due to saprochaete capitata: case report and review of the literature.

Mazzocato S, Marchionni E, Fothergill AW, Sutton DA, Staffolani S, Gesuita R, Skrami E, Fiorentini A, Manso E, Barchiesi F.

Infection. 2015 Apr;43(2):211-5. doi: 10.1007/s15010-014-0668-3. Epub 2014 Jul 31. Review.

PMID:
25078793
18.

Experimental therapy with azoles against Candida guilliermondii.

Sanchis M, Pastor FJ, Capilla J, Sutton DA, Fothergill AW, Guarro J.

Antimicrob Agents Chemother. 2014 Oct;58(10):6255-7. doi: 10.1128/AAC.03051-14. Epub 2014 Jul 21.

19.

Experimental treatment of Curvularia infection.

Paredes K, Capilla J, Sutton DA, Mayayo E, Fothergill AW, Guarro J.

Diagn Microbiol Infect Dis. 2014 Aug;79(4):428-31. doi: 10.1016/j.diagmicrobio.2014.05.004. Epub 2014 May 17.

PMID:
24938759
20.

In vitro antifungal susceptibility of Candida glabrata to caspofungin and the presence of FKS mutations correlate with treatment response in an immunocompromised murine model of invasive infection.

Fernández-Silva F, Lackner M, Capilla J, Mayayo E, Sutton D, Castanheira M, Fothergill AW, Lass-Flörl C, Guarro J.

Antimicrob Agents Chemother. 2014 Jul;58(7):3646-9. doi: 10.1128/AAC.02666-13. Epub 2014 Apr 14.

21.

Phylogeny of the clinically relevant species of the emerging fungus Trichoderma and their antifungal susceptibilities.

Sandoval-Denis M, Sutton DA, Cano-Lira JF, Gené J, Fothergill AW, Wiederhold NP, Guarro J.

J Clin Microbiol. 2014 Jun;52(6):2112-25. doi: 10.1128/JCM.00429-14. Epub 2014 Apr 9.

22.

Luliconazole demonstrates potent in vitro activity against dermatophytes recovered from patients with onychomycosis.

Wiederhold NP, Fothergill AW, McCarthy DI, Tavakkol A.

Antimicrob Agents Chemother. 2014 Jun;58(6):3553-5. doi: 10.1128/AAC.02706-13. Epub 2014 Apr 7.

23.

Therapies against murine Candida guilliermondii infection, relationship between in vitro antifungal pharmacodynamics and outcome.

Paredes K, Pastor FJ, Capilla J, Sutton DA, Mayayo E, Fothergill AW, Guarro J.

Rev Iberoam Micol. 2015 Jan-Mar;32(1):34-9. doi: 10.1016/j.riam.2013.10.008. Epub 2014 Mar 1.

PMID:
24594291
24.

Reply to Ma et al.: osteomyelitis caused by Aspergillus species.

Gabrielli E, Fothergill AW, Brescini L, Sutton DA, Marchionni E, Orsetti E, Staffolani S, Castelli P, Gesuita R, Barchiesi F.

Clin Microbiol Infect. 2014 Oct;20(10):O788. doi: 10.1111/1469-0691.12613. Epub 2014 Mar 26. No abstract available.

25.

Impact of new antifungal breakpoints on antifungal resistance in Candida species.

Fothergill AW, Sutton DA, McCarthy DI, Wiederhold NP.

J Clin Microbiol. 2014 Mar;52(3):994-7. doi: 10.1128/JCM.03044-13. Epub 2014 Jan 8.

26.

In vitro pharmacodynamics and in vivo efficacy of fluconazole, amphotericin B and caspofungin in a murine infection by Candida lusitaniae.

Sandoval-Denis M, Pastor FJ, Capilla J, Sutton DA, Fothergill AW, Guarro J.

Int J Antimicrob Agents. 2014 Feb;43(2):161-4. doi: 10.1016/j.ijantimicag.2013.10.024. Epub 2013 Nov 26.

PMID:
24360922
27.

Osteomyelitis caused by Aspergillus species: a review of 310 reported cases.

Gabrielli E, Fothergill AW, Brescini L, Sutton DA, Marchionni E, Orsetti E, Staffolani S, Castelli P, Gesuita R, Barchiesi F.

Clin Microbiol Infect. 2014 Jun;20(6):559-65. doi: 10.1111/1469-0691.12389. Epub 2013 Oct 15. Review.

28.

A reference laboratory experience of clinically achievable voriconazole, posaconazole, and itraconazole concentrations within the bloodstream and cerebral spinal fluid.

Wiederhold NP, Pennick GJ, Dorsey SA, Furmaga W, Lewis JS 2nd, Patterson TF, Sutton DA, Fothergill AW.

Antimicrob Agents Chemother. 2014;58(1):424-31. doi: 10.1128/AAC.01558-13. Epub 2013 Nov 4.

29.

In vitro antifungal susceptibility of clinical isolates of Arthrographis kalrae, a poorly known opportunistic fungus.

Sandoval-Denis M, Giraldo A, Sutton DA, Fothergill AW, Guarro J.

Mycoses. 2014 Apr;57(4):247-8. doi: 10.1111/myc.12151. Epub 2013 Oct 22.

PMID:
24147779
30.

Scopulariopsis, a poorly known opportunistic fungus: spectrum of species in clinical samples and in vitro responses to antifungal drugs.

Sandoval-Denis M, Sutton DA, Fothergill AW, Cano-Lira J, Gené J, Decock CA, de Hoog GS, Guarro J.

J Clin Microbiol. 2013 Dec;51(12):3937-43. doi: 10.1128/JCM.01927-13. Epub 2013 Sep 11.

31.

Evaluation of the correlation of caspofungin MICs and treatment outcome in murine infections by wild type strains of Candida parapsilosis.

Salas V, Pastor FJ, Capilla J, Sutton DA, Mayayo E, Fothergill AW, Rinaldi MG, Guarro J.

Diagn Microbiol Infect Dis. 2013 Sep;77(1):41-5. doi: 10.1016/j.diagmicrobio.2013.05.011. Epub 2013 Jun 24.

PMID:
23806662
32.

Comparison of MICs of fluconazole and flucytosine when dissolved in dimethyl sulfoxide or water.

Fothergill AW, Sanders C, Wiederhold NP.

J Clin Microbiol. 2013 Jun;51(6):1955-7. doi: 10.1128/JCM.00260-13. Epub 2013 Apr 10.

33.

In vitro antifungal susceptibility and molecular identity of 99 clinical isolates of the opportunistic fungal genus Curvularia.

da Cunha KC, Sutton DA, Fothergill AW, Gené J, Cano J, Madrid H, Hoog Sd, Crous PW, Guarro J.

Diagn Microbiol Infect Dis. 2013 Jun;76(2):168-74. doi: 10.1016/j.diagmicrobio.2013.02.034. Epub 2013 Apr 1.

PMID:
23558007
34.

Virulence of Curvularia in a murine model.

Paredes K, Capilla J, Sutton DA, Mayayo E, Fothergill AW, Guarro J.

Mycoses. 2013 Sep;56(5):512-5. doi: 10.1111/myc.12064. Epub 2013 Feb 26.

PMID:
23437873
35.

MIC values of voriconazole are predictive of treatment results in murine infections by Aspergillus terreus species complex.

Salas V, Pastor FJ, Sutton DA, Calvo E, Mayayo E, Fothergill AW, Rinaldi MG, Guarro J.

Antimicrob Agents Chemother. 2013 Mar;57(3):1532-4. doi: 10.1128/AAC.01436-12. Epub 2013 Jan 7.

36.

Evaluation of the in vitro activity of voriconazole as predictive of in vivo outcome in a murine Aspergillus fumigatus infection model.

Salas V, Pastor FJ, Calvo E, Sutton DA, Fothergill AW, Guarro J.

Antimicrob Agents Chemother. 2013 Mar;57(3):1404-8. doi: 10.1128/AAC.01331-12. Epub 2013 Jan 7.

37.

Rare arthroconidial fungi in clinical samples: Scytalidium cuboideum and Arthropsis hispanica.

Giraldo A, Sutton DA, Gené J, Fothergill AW, Cano J, Guarro J.

Mycopathologia. 2013 Feb;175(1-2):115-21. doi: 10.1007/s11046-012-9590-3. Epub 2012 Oct 17.

PMID:
23073823
38.

Diversity of Bipolaris species in clinical samples in the United States and their antifungal susceptibility profiles.

da Cunha KC, Sutton DA, Fothergill AW, Cano J, Gené J, Madrid H, De Hoog S, Crous PW, Guarro J.

J Clin Microbiol. 2012 Dec;50(12):4061-6. doi: 10.1128/JCM.01965-12. Epub 2012 Oct 10.

39.

Are epidemiologic cut-off values predictors of the in vivo efficacy of azoles in experimental aspergillosis?

Calvo E, Pastor FJ, Sutton DA, Fothergill AW, Rinaldi MG, Salas V, Guarro J.

Diagn Microbiol Infect Dis. 2012 Oct;74(2):158-65. doi: 10.1016/j.diagmicrobio.2012.06.021. Epub 2012 Jul 31.

PMID:
22858549
40.

Molecular identification and antifungal susceptibility testing of clinical isolates of the Candida rugosa species complex and proposal of the new species Candida neorugosa.

Paredes K, Sutton DA, Cano J, Fothergill AW, Lawhon SD, Zhang S, Watkins JP, Guarro J.

J Clin Microbiol. 2012 Jul;50(7):2397-403. doi: 10.1128/JCM.00688-12. Epub 2012 May 2.

41.

Unusual case of cutaneous and synovial Paecilomyces lilacinus infection of hand successfully treated with voriconazole and review of published literature.

Keshtkar-Jahromi M, McTighe AH, Segalman KA, Fothergill AW, Campbell WN.

Mycopathologia. 2012 Sep;174(3):255-8. doi: 10.1007/s11046-012-9540-0. Epub 2012 Apr 8. Review.

PMID:
22484831
42.

In vitro and in vivo activities of posaconazole and amphotericin B in a murine invasive infection by Mucor circinelloides: poor efficacy of posaconazole.

Salas V, Pastor FJ, Calvo E, Alvarez E, Sutton DA, Mayayo E, Fothergill AW, Rinaldi MG, Guarro J.

Antimicrob Agents Chemother. 2012 May;56(5):2246-50. doi: 10.1128/AAC.05956-11. Epub 2012 Jan 30.

43.

Resistant Fusarium keratitis progressing to endophthalmitis.

Edelstein SL, Akduman L, Durham BH, Fothergill AW, Hsu HY.

Eye Contact Lens. 2012 Sep;38(5):331-5. doi: 10.1097/ICL.0b013e318235c5af. Review.

PMID:
21993589
44.

Correlation of susceptibility of Cryptococcus neoformans to amphotericin B with clinical outcome.

Larsen RA, Bauer M, Pitisuttithum P, Sanchez A, Tansuphaswadikul S, Wuthiekanun V, Peacock SJ, Simpson AJ, Fothergill AW, Rinaldi MG, Bustamante B, Thomas AM, Altomstone R, Day NP, White NJ.

Antimicrob Agents Chemother. 2011 Dec;55(12):5624-30. doi: 10.1128/AAC.00034-11. Epub 2011 Sep 26.

45.

The in vitro elution characteristics of antifungal-loaded PMMA bone cement and calcium sulfate bone substitute.

Grimsrud C, Raven R, Fothergill AW, Kim HT.

Orthopedics. 2011 Aug 8;34(8):e378-81. doi: 10.3928/01477447-20110627-05.

PMID:
21815580
46.

Molecular and phenotypic characterization of Phialemonium and Lecythophora isolates from clinical samples.

Perdomo H, Sutton DA, García D, Fothergill AW, Gené J, Cano J, Summerbell RC, Rinaldi MG, Guarro J.

J Clin Microbiol. 2011 Apr;49(4):1209-16. doi: 10.1128/JCM.01979-10. Epub 2011 Jan 26.

47.

Disseminated human conidiobolomycosis due to Conidiobolus lamprauges.

Kimura M, Yaguchi T, Sutton DA, Fothergill AW, Thompson EH, Wickes BL.

J Clin Microbiol. 2011 Feb;49(2):752-6. doi: 10.1128/JCM.01484-10. Epub 2010 Dec 8.

48.

Spectrum of clinically relevant Acremonium species in the United States.

Perdomo H, Sutton DA, García D, Fothergill AW, Cano J, Gené J, Summerbell RC, Rinaldi MG, Guarro J.

J Clin Microbiol. 2011 Jan;49(1):243-56. doi: 10.1128/JCM.00793-10. Epub 2010 Nov 10.

49.

Amphotericin B and natamycin are not synergistic in vitro against Fusarium and Aspergillus spp. isolated from keratitis.

Lalitha P, Shapiro BL, Loh AR, Fothergill AW, Prajna NV, Srinivasan M, Oldenburg CE, Quigley DA, Chidambaram JD, McLeod SD, Acharya NR, Lietman TM.

Br J Ophthalmol. 2011 May;95(5):744-5. doi: 10.1136/bjo.2010.195214. Epub 2010 Oct 28. No abstract available.

50.

Molecular phylogeny and proposal of two new species of the emerging pathogenic fungus Saksenaea.

Alvarez E, Garcia-Hermoso D, Sutton DA, Cano JF, Stchigel AM, Hoinard D, Fothergill AW, Rinaldi MG, Dromer F, Guarro J.

J Clin Microbiol. 2010 Dec;48(12):4410-6. doi: 10.1128/JCM.01646-10. Epub 2010 Oct 6.

Supplemental Content

Loading ...
Support Center